Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial-Reference-Cited by-同舟云学术

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Published:2016-11 Issue:11 Volume:17 Page:1558-1568
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hodi F Stephen,Chesney Jason,Pavlick Anna C,Robert Caroline,Grossmann Kenneth F,McDermott David F,Linette Gerald P,Meyer Nicolas,Giguere Jeffrey K,Agarwala Sanjiv S,Shaheen Montaser,Ernstoff Marc S,Minor David R,Salama April K,Taylor Matthew H,Ott Patrick A,Horak Christine,Gagnier Paul,Jiang Joel,Wolchok Jedd D,Postow Michael A

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. Systematic review of medical treatment in melanoma: current status and future prospects;Garbe;Oncologist,2011

2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

3. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010–20);McDermott;Ann Oncol,2013

4. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;J Clin Oncol,2015

5. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

Cited by 805 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Current Gene Therapy;2025-02

2. A Preliminary Study on the Correlation Between TILs and CTCs and Clinical Value in Lung Cancer Patients Analyzed by Lipid Magnetic Microspheres;Science of Advanced Materials;2024-11-01

3. A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody;Immunobiology;2024-11

4. Neoadjuvant therapy for melanoma: past, present, and future;Surgical Oncology;2024-10

5. Comparison of efficacy between anti‐PD‐1 antibody monotherapy and nivolumab plus ipilimumab therapy as first‐line immunotherapy for advanced mucosal melanoma in Japanese patients: A single‐center, retrospective cohort study;The Journal of Dermatology;2024-09-13